커넥티드형 약물전달 디바이스 시장 규모, 점유율, 성장률 및 세계 업계 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of connected drug delivery devices Market

The global connected drug delivery devices market size was valued at USD 2.15 billion in 2025 and is projected to grow from USD 2.50 billion in 2026 to USD 8.54 billion by 2034, registering a CAGR of 16.59% during the forecast period. North America dominated the market in 2025, supported by advanced healthcare infrastructure, strong adoption of digital health technologies, and the presence of leading connected-device companies.

Market Definition and Scope

Connected drug delivery devices combine conventional drug administration with Bluetooth, NFC, cloud connectivity, IoT, and digital health technologies. These devices can provide dose reminders, adherence tracking, patient diaries, monitoring capabilities, and educational support. They are increasingly used for chronic conditions such as asthma, COPD, diabetes, and cardiovascular disorders, helping healthcare providers monitor treatment and improve patient engagement.

Market Dynamics

Drivers

The rising prevalence of chronic diseases is a major factor supporting market growth. Increasing cases of asthma, COPD, diabetes, and other long-term disorders are creating demand for technologies that improve medication adherence and treatment monitoring. The shift from conventional drug delivery devices toward connected solutions is also supported by their ability to provide real-time information and improve procedural outcomes.

Trends

Integration of Bluetooth-enabled systems, artificial intelligence, cloud platforms, and IoT is becoming an important trend. Smart inhalers and connected injectable devices can communicate with smartphones and digital platforms, allowing patients and healthcare professionals to monitor medication use remotely. Increasing adoption of preventive healthcare and personalized treatment is further supporting technological development.

Restraints

High device costs, regulatory requirements, data-security concerns, and variations in healthcare reimbursement policies can limit adoption, particularly in price-sensitive markets. The need for interoperability between connected devices and existing healthcare information systems can also create implementation challenges.

Impact of COVID-19

The COVID-19 pandemic accelerated the adoption of remote patient monitoring and digital healthcare technologies. Reduced opportunities for frequent in-person consultations increased the importance of connected devices capable of supporting medication adherence and remote monitoring. This shift helped create greater awareness of digitally enabled drug delivery solutions and encouraged healthcare providers to consider connected technologies for chronic disease management.

Segmentation Analysis

By Type, the market is divided into injectable devices and inhalation devices & others. Injectable devices are expected to maintain a dominant position, supported by increasing demand for smart injection technologies and the growing prevalence of diabetes, cancer, and neurological disorders. Inhalation devices are also gaining importance due to the widespread use of connected solutions for asthma and COPD management.

By Technology, the market includes Bluetooth, NFC, and others. Bluetooth is expected to remain prominent because of its smartphone compatibility, ease of use, and broad integration across connected drug delivery systems. NFC technology is also gaining attention because of its data-transfer capabilities and potential battery-life advantages.

By End User, the market is categorized into homecare settings and hospitals. Homecare settings are expected to lead as patients increasingly manage chronic conditions outside hospitals and require convenient adherence monitoring and dose reminders.

Regional Insights

North America accounted for 70.06% of the global market in 2025, making it the leading region. Strong healthcare infrastructure, high healthcare expenditure, technological adoption, and the presence of major industry participants support regional growth.

Europe is expected to record a 34.5% CAGR, driven by increasing adoption of connected medical devices in Germany, the U.K., and France and greater emphasis on improving patient experiences.

Asia Pacific is expected to experience significant growth because of rising healthcare awareness, improving medical infrastructure, and increasing adoption of advanced technologies in China and India. China is projected to witness a strong 56.70% CAGR, while Japan's market is expected to reach USD 183.2 million in 2025.

Competitive Landscape

The connected drug delivery devices market is characterized by active competition among technology developers, pharmaceutical companies, and medical-device manufacturers. Companies are focusing on product development, technological innovation, strategic partnerships, regulatory clearances, and expansion of distribution networks to strengthen their market positions.

List of Key Connected Drug Delivery Devices Companies

• Proteus Digital Health
• Ypsomed Holding
• F. Hoffmann-La Roche Ltd.
• BD
• West Pharmaceutical Services
• Propeller Health (A ResMed Company)
• Adherium
• Cohero Health, Inc.

Recent Industry Developments

In June 2021, Adherium Limited submitted a 510(k) application to the U.S. FDA for its first-generation Hailie sensor designed to monitor asthma and COPD medication use. In November 2019, Lupin launched ADHERO, a connected metered-dose inhaler designed to help patients track medication usage and improve adherence.

Report Coverage

The connected drug delivery devices market analysis covers market drivers, restraints, trends, segmentation, regional performance, competitive developments, technological advancements, product launches, partnerships, and regulatory developments. The report evaluates the adoption of connected drug delivery technologies across different product types, technologies, and end-user settings and highlights emerging opportunities associated with digital healthcare and chronic disease management.

Connected Drug Delivery Devices Market Size and Market Value by Year

• 2025 Market Size: USD 2.15 billion
• 2026 Market Size: USD 2.50 billion
• 2034 Forecast Market Size: USD 8.54 billion
• Market CAGR: 16.59% during 2026-2034

Conclusion

The connected drug delivery devices market is positioned for strong expansion as healthcare systems increasingly adopt digital technologies for medication adherence, remote monitoring, and personalized treatment. Growing chronic disease prevalence, smartphone connectivity, Bluetooth, NFC, IoT, and AI integration are creating new opportunities for connected drug delivery solutions. North America currently leads the market, while Europe and Asia Pacific offer substantial growth opportunities. Continued product innovation, regulatory approvals, strategic collaborations, and increasing adoption of home-based healthcare are expected to remain important factors shaping the market through 2034.

Unit Value (USD million)

Segmentation By Type

• Injectable Devices
• Inhalation Devices and Others

By Technology

• Bluetooth
• NFC (Near Field Communication)
• Others

By End User

• Homecare Settings
• Hospitals

By Region

• North America
• Europe
• Asia Pacific
• Rest of the World

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Technological advancements in Connected Drug Delivery Devices Market
• 4.2. Recent Industry Developments- Partnerships, Mergers, And Acquisitions
• 4.3. New Product Launches by Key Players
• 4.4. Regulatory Scenarios
• 4.5. Trends of Usage of Connected Drug Delivery Devices

5. Global Connected Drug Delivery Devices Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. Injectable Devices
  • 5.2.2. Inhalation Devices and Others
• 5.3. Market Analysis, Insights and Forecast - By Technology
  • 5.3.1. Bluetooth
  • 5.3.2. NFC (Near Field Communication)
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Homecare Settings
  • 5.4.2. Hospitals
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia pacific
  • 5.5.4. Rest of the World

6. North America Connected Drug Delivery Devices Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Type
  • 6.2.1. Injectable Devices
  • 6.2.2. Inhalation Devices and Others
• 6.3. Market Analysis - By Technology
  • 6.3.1. Bluetooth
  • 6.3.2. NFC (Near Field Communication)
  • 6.3.3. Others
• 6.4. Market Analysis - By End User
  • 6.4.1. Homecare Settings
  • 6.4.2. Hospitals
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Connected Drug Delivery Devices Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Type
  • 7.2.1. Injectable Devices
  • 7.2.2. Inhalation Devices and Others
• 7.3. Market Analysis - By Technology
  • 7.3.1. Bluetooth
  • 7.3.2. NFC (Near Field Communication)
  • 7.3.3. Others
• 7.4. Market Analysis - By End User
  • 7.4.1. Homecare Settings
  • 7.4.2. Hospitals
• 7.5. Market Analysis - By Country/ Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Rest of Europe

8. Asia pacific Connected Drug Delivery Devices Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Type
  • 8.2.1. Injectable Devices
  • 8.2.2. Inhalation Devices and Others
• 8.3. Market Analysis - By Technology
  • 8.3.1. Bluetooth
  • 8.3.2. NFC (Near Field Communication)
  • 8.3.3. Others
• 8.4. Market Analysis - By End User
  • 8.4.1. Homecare Settings
  • 8.4.2. Hospitals
• 8.5. Market Analysis - By Country/ Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Rest of Asia Pacific

9. Rest of the World Connected Drug Delivery Devices Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Type
  • 9.2.1. Injectable Devices
  • 9.2.2. Inhalation Devices and Others
• 9.3. Market Analysis - By Technology
  • 9.3.1. Bluetooth
  • 9.3.2. NFC (Near Field Communication)
  • 9.3.3. Others
• 9.4. Market Analysis - By End User
  • 9.4.1. Homecare Settings
  • 9.4.2. Hospitals

10. Competitive Analysis

• 10.1. Key Industry Developments
• 10.2. Global Market Share Analysis (2025)
• 10.3. Competition Dashboard
• 10.4. Comparative Analysis - Major Players
• 10.5. Company Profiles
  • 10.5.1. Proteus Digital Health
    • 10.5.1.1. Overview,
    • 10.5.1.2. Products & Services,
    • 10.5.1.3. SWOT Analysis,
    • 10.5.1.4. Recent Developments,
    • 10.5.1.5. Strategies,
    • 10.5.1.6. Financials (Based on Availability)
  • 10.5.2. Ypsomed Holding
    • 10.5.2.1. Overview,
    • 10.5.2.2. Products & Services,
    • 10.5.2.3. SWOT Analysis,
    • 10.5.2.4. Recent Developments,
    • 10.5.2.5. Strategies,
    • 10.5.2.6. Financials (Based on Availability)
  • 10.5.3. F. Hoffmann-La Roche Ltd
    • 10.5.3.1. Overview,
    • 10.5.3.2. Products & Services,
    • 10.5.3.3. SWOT Analysis,
    • 10.5.3.4. Recent Developments,
    • 10.5.3.5. Strategies,
    • 10.5.3.6. Financials (Based on Availability)
  • 10.5.4. BD
    • 10.5.4.1. Overview,
    • 10.5.4.2. Products & Services,
    • 10.5.4.3. SWOT Analysis,
    • 10.5.4.4. Recent Developments,
    • 10.5.4.5. Strategies,
    • 10.5.4.6. Financials (Based on Availability)
  • 10.5.5. West Pharmaceutical Services
    • 10.5.5.1. Overview,
    • 10.5.5.2. Products & Services,
    • 10.5.5.3. SWOT Analysis,
    • 10.5.5.4. Recent Developments,
    • 10.5.5.5. Strategies,
    • 10.5.5.6. Financials (Based on Availability)
  • 10.5.6. Propeller Health (A ResMed Company)
    • 10.5.6.1. Overview,
    • 10.5.6.2. Products & Services,
    • 10.5.6.3. SWOT Analysis,
    • 10.5.6.4. Recent Developments,
    • 10.5.6.5. Strategies,
    • 10.5.6.6. Financials (Based on Availability)
  • 10.5.7. Adherium
    • 10.5.7.1. Overview,
    • 10.5.7.2. Products & Services,
    • 10.5.7.3. SWOT Analysis,
    • 10.5.7.4. Recent Developments,
    • 10.5.7.5. Strategies,
    • 10.5.7.6. Financials (Based on Availability)
  • 10.5.8. Cohero Health, Inc.
    • 10.5.8.1. Overview,
    • 10.5.8.2. Products & Services,
    • 10.5.8.3. SWOT Analysis,
    • 10.5.8.4. Recent Developments,
    • 10.5.8.5. Strategies,
    • 10.5.8.6. Financials (Based on Availability)
  • 10.5.9. Other Prominent Players
    • 10.5.9.1. Overview,
    • 10.5.9.2. Products & Services,
    • 10.5.9.3. SWOT Analysis,
    • 10.5.9.4. Recent Developments,
    • 10.5.9.5. Strategies,
    • 10.5.9.6. Financials (Based on Availability)

11. Strategic Recommendations